Related Experiment Videos
Clinical experience with NovoPen II and insulin Protaphane HM Penfill
K Kølendorf1, H Beck-Nielsen, B Oxenbøll
1Medical Department, Sundby Hospital, Copenhagen, Denmark.
Postgraduate Medical Journal
|January 1, 1988
Summary
Intermediate-acting insulin Protaphane HM in Penfill is safe and convenient for diabetes management. Most patients preferred the NovoPen device over traditional syringes for easier insulin delivery.
Area of Science:
- Endocrinology
- Pharmacology
- Diabetes Mellitus Management
Background:
- Intermediate-acting insulin Protaphane HM is available in Penfill cartridges.
- Convenience and safety of insulin delivery devices are crucial for diabetes self-management.
Purpose of the Study:
- To evaluate the acceptance and convenience of Protaphane HM in Penfill compared to vials.
- To assess the safety of administering Protaphane HM using the NovoPen system in patients with insulin-dependent diabetes mellitus.
Main Methods:
- Randomized, cross-over, within-patient comparison study.
- Involved 19 insulin-dependent diabetes mellitus patients over two 12-week periods.
- Safety assessed via blood glucose profiles, HbA1c, insulin dosage, and hypoglycemia frequency; acceptance via questionnaire.
Main Results:
- No statistically significant differences in safety parameters between Penfill and vial administration.
- 17 of 19 patients found NovoPen easier and quicker to use than conventional syringes.
- 52 of 55 patients preferred NovoPen II for continued use, with 51 finding dose preselection easy.
Conclusions:
- Insulin Protaphane HM in Penfill is safe for administration with the NovoPen system.
- The NovoPen system offers improved convenience and acceptance for patients with insulin-dependent diabetes mellitus.